Plant Name: Viscum album
Collective Molecular Activities at 10μM Activity Cutoff
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| GPBAR1; FFAR1; FFAR4; | |
| PTPN1; PTPN2; ACP1; PTPRF; CDC25B; | |
| RECQL; PLA2G1B; HPGD; HSD11B1; AKR1B10; ALOX15; POLB; | |
| PRKCA; | |
| PPARA; PPARD; PPARG; | |
| RORC; | |
| NR1H4; | |
| TLR2; | |
| HIF1A; | |
| LMNA; FABP3; FABP2; FABP4; MAPT; FABP5; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
Detailed Information of Human Protein Targets
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Cytochrome P450 family 1 | CYP1B1 | Cytochrome P450 1B1 | Q16678 | CHEMBL4878 |
| Cytochrome P450 family 2 | CYP2C9 | Cytochrome P450 2C9 | P11712 | CHEMBL3397 |
| Enzyme_unclassified | POLB | DNA polymerase beta | P06746 | CHEMBL2392 |
| Enzyme_unclassified | RECQL | ATP-dependent DNA helicase Q1 | P46063 | CHEMBL1293236 |
| Enzyme_unclassified | PLA2G1B | Phospholipase A2 group 1B | P04054 | CHEMBL4426 |
| Enzyme_unclassified | HPGD | 15-hydroxyprostaglandin dehydrogenase [NAD+] | P15428 | CHEMBL1293255 |
| Enzyme_unclassified | HSD11B1 | 11-beta-hydroxysteroid dehydrogenase 1 | P28845 | CHEMBL4235 |
| Enzyme_unclassified | AKR1B10 | Aldo-keto reductase family 1 member B10 | O60218 | CHEMBL5983 |
| Enzyme_unclassified | ALOX15 | Arachidonate 15-lipoxygenase | P16050 | CHEMBL2903 |
| Nuclear hormone receptor subfamily 1 group C | PPARA | Peroxisome proliferator-activated receptor alpha | Q07869 | CHEMBL239 |
| Nuclear hormone receptor subfamily 1 group C | PPARD | Peroxisome proliferator-activated receptor delta | Q03181 | CHEMBL3979 |
| Nuclear hormone receptor subfamily 1 group C | PPARG | Peroxisome proliferator-activated receptor gamma | P37231 | CHEMBL235 |
| Nuclear hormone receptor subfamily 1 group F | RORC | Nuclear receptor ROR-gamma | P51449 | CHEMBL1741186 |
| Nuclear hormone receptor subfamily 1 group H | NR1H4 | Bile acid receptor FXR | Q96RI1 | CHEMBL2047 |
| Protein Kinase | PRKCA | Protein kinase C alpha | P17252 | CHEMBL299 |
| Protein Phosphatase | PTPN1 | Protein-tyrosine phosphatase 1B | P18031 | CHEMBL335 |
| Protein Phosphatase | PTPN2 | T-cell protein-tyrosine phosphatase | P17706 | CHEMBL3807 |
| Protein Phosphatase | ACP1 | Low molecular weight phosphotyrosine protein phosphatase | P24666 | CHEMBL4903 |
| Protein Phosphatase | PTPRF | Receptor-type tyrosine-protein phosphatase F (LAR) | P10586 | CHEMBL3521 |
| Protein Phosphatase | CDC25B | Dual specificity phosphatase Cdc25B | P30305 | CHEMBL4804 |
| Small molecule receptor (family A GPCR) | GPBAR1 | G-protein coupled bile acid receptor 1 | Q8TDU6 | CHEMBL5409 |
| Small molecule receptor (family A GPCR) | FFAR1 | Free fatty acid receptor 1 | O14842 | CHEMBL4422 |
| Small molecule receptor (family A GPCR) | FFAR4 | G-protein coupled receptor 120 | Q5NUL3 | CHEMBL5339 |
| Toll-like and Il-1 receptors | TLR2 | Toll-like receptor 2 | O60603 | CHEMBL4163 |
| Transcription Factor | HIF1A | Hypoxia-inducible factor 1 alpha | Q16665 | CHEMBL4261 |
| Unclassified | MAPT | Microtubule-associated protein tau | P10636 | CHEMBL1293224 |
| Unclassified | FABP5 | Fatty acid binding protein epidermal | Q01469 | CHEMBL3674 |
| Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
| Unclassified | FABP3 | Fatty acid binding protein muscle | P05413 | CHEMBL3344 |
| Unclassified | FABP2 | Fatty acid binding protein intestinal | P12104 | CHEMBL4879 |
| Unclassified | FABP4 | Fatty acid binding protein adipocyte | P15090 | CHEMBL2083 |
Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| MF | GO:0140110; transcription regulator activity | GO:0004879; nuclear receptor activity | 1.377E-08 | 1.593E-05 | NR1H4, PPARA, PPARD, PPARG, RORC |
| BP | GO:0050896; response to stimulus | GO:0050728; negative regulation of inflammatory response | 2.546E-08 | 2.640E-05 | FFAR4, NR1H4, PPARA, PPARD, PPARG, PTPN2 |
| MF | GO:0060089; molecular transducer activity | GO:0003707; steroid hormone receptor activity | 3.575E-08 | 3.384E-05 | NR1H4, PPARA, PPARD, PPARG, RORC |
| BP | GO:0008152; metabolic process | GO:0019433; triglyceride catabolic process | 6.705E-08 | 5.723E-05 | FABP2, FABP3, FABP4, FABP5 |
| BP | GO:0050896; response to stimulus | GO:0070542; response to fatty acid | 1.676E-07 | 1.141E-04 | FABP3, FFAR1, NR1H4, PPARG, TLR2 |
| BP | GO:0008152; metabolic process | GO:0035335; peptidyl-tyrosine dephosphorylation | 4.882E-07 | 2.593E-04 | ACP1, CDC25B, PTPN1, PTPN2, PTPRF |
| BP | GO:0009987; cellular process | GO:0043401; steroid hormone mediated signaling pathway | 1.887E-06 | 7.415E-04 | NR1H4, PPARA, PPARD, PPARG, RORC |
| BP | GO:0008152; metabolic process | GO:0008202; steroid metabolic process | 2.317E-06 | 8.852E-04 | AKR1B10, CYP1B1, CYP2C9, HSD11B1, NR1H4, PPARD |
| BP | GO:0050896; response to stimulus | GO:0032868; response to insulin | 2.624E-06 | 9.523E-04 | FABP3, PLA2G1B, PPARA, PPARG, TLR2 |
| BP | GO:0023052; signaling | GO:0032024; positive regulation of insulin secretion | 4.114E-06 | 1.266E-03 | FFAR1, HIF1A, NR1H4, PPARD |
| BP | GO:0065007; biological regulation | GO:0042593; glucose homeostasis | 5.071E-06 | 1.373E-03 | FFAR1, HIF1A, NR1H4, PPARG, PTPN2 |
| BP | GO:0008152; metabolic process | GO:0006367; transcription initiation from RNA polymerase II promoter | 5.229E-06 | 1.373E-03 | NR1H4, PPARA, PPARD, PPARG, RORC |
| BP | GO:0009987; cellular process | GO:0038183; bile acid signaling pathway | 7.471E-06 | 1.807E-03 | GPBAR1, NR1H4 |
| MF | GO:0060089; molecular transducer activity | GO:0038181; bile acid receptor activity | 7.471E-06 | 1.807E-03 | GPBAR1, NR1H4 |
| BP | GO:0009987; cellular process | GO:0030522; intracellular receptor signaling pathway | 8.092E-06 | 1.915E-03 | NR1H4, PPARA, PPARD, PPARG, RORC |
| BP | GO:0065007; biological regulation | GO:0044092; negative regulation of molecular function | 8.790E-06 | 2.058E-03 | CYP1B1, FABP4, MAPT, NR1H4, PPARA, PPARG, PRKCA, PTPN1, PTPN2, PTPRF |
| BP | GO:0032501; multicellular organismal process | GO:0001816; cytokine production | 9.128E-06 | 2.092E-03 | FABP4, HIF1A, PLA2G1B, TLR2 |
| BP | GO:0009987; cellular process | GO:0071310; cellular response to organic substance | 1.270E-05 | 2.635E-03 | ALOX15, CYP1B1, FABP4, FFAR4, HIF1A, NR1H4, PLA2G1B, PPARD, PPARG, RORC |
| BP | GO:0009987; cellular process | GO:1902202; regulation of hepatocyte growth factor receptor signaling pathway | 1.493E-05 | 2.954E-03 | PTPN1, PTPN2 |
| BP | GO:0009987; cellular process | GO:1902533; positive regulation of intracellular signal transduction | 1.560E-05 | 2.980E-03 | ALOX15, CYP1B1, FFAR4, PLA2G1B, PPARD, PRKCA, PTPN1, PTPN2, TLR2 |
| BP | GO:0008152; metabolic process | GO:0006691; leukotriene metabolic process | 1.632E-05 | 3.063E-03 | ALOX15, PLA2G1B, TLR2 |
| MF | Unclassified; | GO:0004872; receptor activity | 1.659E-05 | 3.087E-03 | FFAR1, FFAR4, GPBAR1, HPGD, NR1H4, PPARA, PPARD, PPARG, PTPRF, RORC, TLR2 |
| BP | GO:0051179; localization | GO:0010891; negative regulation of sequestering of triglyceride | 2.485E-05 | 4.313E-03 | PPARA, PPARG |
| BP | GO:0065007; biological regulation | GO:0055088; lipid homeostasis | 2.782E-05 | 4.741E-03 | FABP3, FABP4, NR1H4, PPARG |
| BP | GO:0051179; localization | GO:0010887; negative regulation of cholesterol storage | 3.724E-05 | 5.963E-03 | PPARA, PPARG |
| BP | GO:0009987; cellular process | GO:0060336; negative regulation of interferon-gamma-mediated signaling pathway | 3.724E-05 | 5.963E-03 | PPARG, PTPN2 |
| BP | GO:0008152; metabolic process | GO:0010871; negative regulation of receptor biosynthetic process | 3.724E-05 | 5.963E-03 | PPARA, PPARG |
| BP | GO:0008152; metabolic process | GO:2001300; lipoxin metabolic process | 3.724E-05 | 5.963E-03 | ALOX15, HPGD |
| MF | GO:0005488; binding | GO:0050543; icosatetraenoic acid binding | 3.724E-05 | 5.963E-03 | FABP3, PPARG |
| BP | GO:0008152; metabolic process | GO:0045834; positive regulation of lipid metabolic process | 4.312E-05 | 6.660E-03 | FABP3, NR1H4, PPARA, PPARG |
| BP | GO:0008152; metabolic process | GO:1901615; organic hydroxy compound metabolic process | 4.370E-05 | 6.701E-03 | AKR1B10, ALOX15, CYP1B1, HIF1A, NR1H4, PPARD |
| BP | GO:0009987; cellular process | GO:0071453; cellular response to oxygen levels | 4.887E-05 | 7.239E-03 | HIF1A, LMNA, PPARD, PPARG |
| BP | GO:0008152; metabolic process | GO:0055114; oxidation-reduction process | 6.419E-05 | 9.195E-03 | AKR1B10, ALOX15, CYP1B1, CYP2C9, HPGD, HSD11B1, PPARD, PPARG |
| BP | GO:0050896; response to stimulus | GO:0046626; regulation of insulin receptor signaling pathway | 6.559E-05 | 9.335E-03 | NR1H4, PTPN1, PTPN2 |
| BP | GO:0008152; metabolic process | GO:0051173; positive regulation of nitrogen compound metabolic process | 6.928E-05 | 9.586E-03 | ALOX15, CDC25B, FFAR4, HIF1A, MAPT, NR1H4, PLA2G1B, PPARA, PPARD, PPARG, PRKCA, PTPN1, RORC, TLR2 |
| BP | GO:0009987; cellular process | GO:0070372; regulation of ERK1 and ERK2 cascade | 6.955E-05 | 9.586E-03 | ALOX15, FFAR4, PRKCA, PTPN1, PTPN2 |
| MF | GO:0003824; catalytic activity | GO:0004726; non-membrane spanning protein tyrosine phosphatase activity | 6.938E-05 | 9.586E-03 | ACP1, PTPN2 |
Enriched KEGG Pathways of Target Proteins (Activity≤10μM)
Top 10, ordered by adjusted p-value
Detailed Information of Enriched KEGG Pathways
| Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|
| hsa03320 | PPAR signaling pathway_Homo sapiens_hsa03320 | 1.048E-11 | 1.278E-09 | FABP2; FABP3; FABP4; FABP5; PPARG; PPARA; PPARD |
| hsa00591 | Linoleic acid metabolism_Homo sapiens_hsa00591 | 1.199E-05 | 7.313E-04 | CYP2C9; PLA2G1B; ALOX15 |
| hsa00590 | Arachidonic acid metabolism_Homo sapiens_hsa00590 | 1.199E-04 | 4.874E-03 | CYP2C9; PLA2G1B; ALOX15 |
| hsa00980 | Metabolism of xenobiotics by cytochrome P450_Homo sapiens_hsa00980 | 1.949E-04 | 4.950E-03 | HSD11B1; CYP2C9; CYP1B1 |
| hsa04520 | Adherens junction_Homo sapiens_hsa04520 | 2.029E-04 | 4.950E-03 | PTPN1; ACP1; PTPRF |
| hsa05204 | Chemical carcinogenesis_Homo sapiens_hsa05204 | 2.748E-04 | 5.589E-03 | HSD11B1; CYP2C9; CYP1B1 |
| hsa04931 | Insulin resistance_Homo sapiens_hsa04931 | 6.334E-04 | 1.045E-02 | PTPN1; PPARA; PTPRF |
| hsa04726 | Serotonergic synapse_Homo sapiens_hsa04726 | 6.855E-04 | 1.045E-02 | CYP2C9; ALOX15; PRKCA |
| hsa05200 | Pathways in cancer_Homo sapiens_hsa05200 | 3.149E-03 | 3.652E-02 | PRKCA; PPARG; HIF1A; PPARD |
| hsa05205 | Proteoglycans in cancer_Homo sapiens_hsa05205 | 3.756E-03 | 3.652E-02 | PRKCA; HIF1A; TLR2 |
| hsa04975 | Fat digestion and absorption_Homo sapiens_hsa04975 | 1.836E-03 | 2.489E-02 | FABP2; PLA2G1B |
| hsa04150 | mTOR signaling pathway_Homo sapiens_hsa04150 | 3.891E-03 | 3.652E-02 | PRKCA; HIF1A |
| hsa05321 | Inflammatory bowel disease (IBD)_Homo sapiens_hsa05321 | 4.551E-03 | 3.966E-02 | RORC; TLR2 |
| hsa00140 | Steroid hormone biosynthesis_Homo sapiens_hsa00140 | 3.641E-03 | 3.652E-02 | HSD11B1; CYP1B1 |
Human Diseases Associated with the Target Proteins of the Plant (Activity≤10μM)
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Linked Targets |
|---|---|---|---|
| I00-I99: Diseases of the circulatory system | Pulmonary arterial hypertension | I27.0, I27.2 | HIF1A |
| N00-N99: Diseases of the genitourinary system | Endometriosis | N80 | PPARG |
| H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | HSD11B1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Non-insulin dependent diabetes | E11.9 | HSD11B1; FFAR1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Nicotine dependence | F17 | PPARG |
| G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | MAPT |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Nerve injury | T14.4 | PLA2G1B |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Radiation sickness | T66 | TLR2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | PTPN1; HSD11B1; HSD11B1; FFAR1; PPARG |
| C00-D49: Neoplasms | Myelodysplastic syndrome | D46 | TLR2 |
| J00-J99: Diseases of the respiratory system | Influenza virus | J11.1 | HSD11B1 |
| C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | PLA2G1B |
| K00-K95: Diseases of the digestive system | Inflammatory bowel disease | K50, K51 | PPARG |
| L00-L99: Diseases of the skin and subcutaneous tissue | Inflammatory and pruritic manifestations of corticosteroid responsive dermatoses | L20-L30 | PLA2G1B |
| L00-L99: Diseases of the skin and subcutaneous tissue | Inflammatory and pruritic manifestations of moderate to severe corticosteroid-responsive dermatoses of the scalp | L20-L30 | PLA2G1B |
| C00-D49: Neoplasms | Pancreatic cancer | C25 | TLR2 |
| K00-K95: Diseases of the digestive system | Non-alcoholic fatty liver disease | K76.0 | PPARD; PPARG |
| A00-B99: Certain infectious and parasitic diseases | Leishmaniasis | B55.0 | PLA2G1B |
| E00-E89: Endocrine, nutritional and metabolic diseases | Lipid metabolism disorder | E75-E78 | HSD11B1 |
| I00-I99: Diseases of the circulatory system | Atherosclerosis | I70 | HSD11B1; PPARD |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | PLA2G1B |
| I00-I99: Diseases of the circulatory system | Arteriosclerosis | I70 | PLA2G1B |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperlipidaemia | E78 | PPARD |
| C00-D49: Neoplasms | Lymphoma | C81-C86 | HIF1A |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | MAPT; PPARG; PPARG |
| H00-H59: Diseases of the eye and adnexa | Ocular inflammation | H16.229 | PPARG |
| A00-B99: Certain infectious and parasitic diseases | Bacterial infections | A00-B99 | CYP2C9 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hypercholesterolemia | E78 | HSD11B1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | PPARG |
| E00-E89: Endocrine, nutritional and metabolic diseases | Obesity | E66 | PTPN1; HSD11B1; PPARD; PPARD; PPARG |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | MAPT |
| C00-D49: Neoplasms | Melanoma | C43 | TLR2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Metabolic syndrome x | E88.81 | HSD11B1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Metabolic disorders | E70-E89 | GPBAR1; HSD11B1 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Allergy | T78.4 | PLA2G1B |
| J00-J99: Diseases of the respiratory system | Allergic rhinitis | J00, J30, J31.0, T78.4 | PLA2G1B |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Drug abuse | F10-F19 | PPARG |
| C00-D49: Neoplasms | Cancer | C00-C96 | HIF1A; CDC25B; TLR2 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Contact dermatitis | L23, L24, L25 | PLA2G1B |
| NA: NA | Colour dead tissues | NA | PTPN1 |
| A00-B99: Certain infectious and parasitic diseases | Infections | A00-B99 | PTPN1 |
| C00-D49: Neoplasms | Prostate cancer | C61 | TLR2 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Pruritus | L29 | PLA2G1B |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 1 diabetes | E10 | PPARD; PPARG |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | PTPN1; PTPN1; GPBAR1; HSD11B1; FFAR1; PPARD; PPARG; PPARG |
| A00-B99: Certain infectious and parasitic diseases | Visceral leishmaniasis | B55.0 | PLA2G1B |
| G00-G99: Diseases of the nervous system G00-G99 | Central nervous system disease | G00-G99 | PPARD; MAPT |
| E00-E89: Endocrine, nutritional and metabolic diseases | Autoimmune diabetes | E08-E13 | TLR2 |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | HIF1A; TLR2 |
| NA: NA | Dyslipidemia | NA | PPARD |
| E00-E89: Endocrine, nutritional and metabolic diseases | Dyslipidaemias | E78 | PPARD; PPARD |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | PLA2G1B |
| J00-J99: Diseases of the respiratory system | Asthma | J45 | PLA2G1B |